



National Comprehensive
Cancer Network®

For Immediate Release:
October 15, 2020

Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org

NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers

Research projects will explore the role of this tyrosine kinase inhibitor in different tumor types.

PLYMOUTH MEETING, PA [October 15, 2020] — The National Comprehensive Cancer Network® ([NCCN](#)®) Oncology Research Program ([ORP](#)) today announced plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2). The research funding is supported by a \$2-million grant from Puma Biotechnology, Inc.

Projects may include pre-clinical, translational and clinical trials. They will focus on treatment of:

- Pediatric tumors(including neurofibromatosis Type 2 and progressive Vestibular Schwannoma)
- Early-stage and metastatic breast cancer, including those with HER2+ brain metastases
- Other HER2-amplified tumors
- EGFR-mutated glioblastoma multiforme.

Specific research areas will be determined by a group of cancer research experts from [NCCN Member Institutions](#) who form a Request for Proposals (RFP) Development Team.

“We look forward to advancing knowledge of the role this dual HER breast cancer drug may have in improving outcomes for various cancer presentations,” said **Wui-Jin Koh, MD, Chief Medical Officer, NCCN**. “The projects we oversee will provide important information on this emerging mechanism for personalized cancer care.”

“We thank the National Comprehensive Cancer Network for their inclusion of neratinib for further evaluation,” said **Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology**. “We are proud to support NCCN’s research projects to better understand the full potential of neratinib across a variety of indications. Our goal is to use these insights to expand the potential indications, as well as to identify patients who may benefit from neratinib.”

The first phase of this project will involve the creation of an RFP, which will open in early 2021. The awarded projects will be announced following review of submitted proposals.

The NCCN ORP fosters innovation and knowledge discovery that improves the lives of people with cancer and supports preclinical, translational, and clinical research and quality improvement projects in oncology at NCCN Member Institutions. In an effort to improve collaboration in cancer

Page 2 NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers

research, the NCCN ORP also maintains a [shared resources website](#) and an [informed consent database](#). For more information, visit NCCN.org/orp.

###

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® ([NCCN](#)®) is a not-for-profit alliance of [leading cancer centers](#) devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology ([NCCN Guidelines](#)®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The [NCCN Guidelines for Patients](#)® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the [NCCN Foundation](#)®. NCCN also advances [continuing education](#), [global initiatives](#), [policy](#), and research [collaboration](#) and [publication](#) in oncology. Visit NCCN.org for more information and follow NCCN on Facebook [@NCCNorg](#), Instagram [@NCCNorg](#), and Twitter [@NCCN](#).